Hostname: page-component-8448b6f56d-qsmjn Total loading time: 0 Render date: 2024-04-19T01:43:33.362Z Has data issue: false hasContentIssue false

A Double-Blind Trial to Investigate the Effects of Thorazine (Largactil, Chlorpromazine), Compazine (Stemetil, Prochlorperazine) and Stelazine (Trifluoperazine) in Paranoid Schizophrenia

Published online by Cambridge University Press:  08 February 2018

Ian C. Wilson
Affiliation:
Broughton Hospital
James Mckay
Affiliation:
Broughton Hospital
Myron G. Sandifer Jr.
Affiliation:
North Carolina State Hospital System

Extract

In the early phenothiazine literature the ataractic properties of Thorazine in the control of disturbed, hyperactive schizophrenics were described (Kurland, 1955; Hall and Dunlap, 1955; Lehmann, 1955). Kurland (1955) gives an excellent description of the powerful activity of Thorazine in this sphere, namely the control of hyperkinesis and hostile, aggressive behaviour; however, he found that there was little basic change in delusional thought disorder other than to divorce the abnormal thinking from its affective attachment. It was noted that the clinical improvement was most dramatic when the affective component of the illness was most marked. Hall and Dunlap (1955) felt that there was significant reduction in delusional ideation but noted that the schizophrenic process was not affected by Thorazine medication.

Type
Original Articles
Copyright
Copyright © Royal College of Psychiatrists, 1961 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Barsa, J. A., Saunders, J. C., and Kline, N. S., Am. J. Psychiat., 1959, 115, 812.Google Scholar
2. Clyde, D. J., Psychopharmacology Service Center, N.I.M.H., Bethesda, Maryland.Google Scholar
3. Denber, H. C. B., Psychiat. Res. Rep., 1958, 9, 1622.Google Scholar
4. Denham, J., J. Ment. Sci., 1958, 104, 11901194.Google Scholar
5. Dransfield, G. A., J. Ment. Sci., 1958, 104, 11831189.CrossRefGoogle Scholar
6. Feldman, P. E., Trifluoperazine, 1958. Philadelphia: Lea and Febiger.Google Scholar
7. Forrester, M. E., Brit. Med. J., 1958, ii, 90.Google Scholar
8. Freyhan, F. A., Psychiat. Res. Rep., 1958, 9, 2331.Google Scholar
9. Frierson, B. D., J. Nerv. Ment. Dis., 1958, 126, 585586.CrossRefGoogle Scholar
10. Goldman, D., Psychiat. Res. Rep., 1958, 9, 2331.Google Scholar
11. Hall, R., and Dunlap, D., J. Nerv. Ment. Dis., 1955, 122, 301314.Google Scholar
12. Hanlon, T. E., Kurland, A., Esquibel, A. J., and Ota, K. Y., J. Nerv. Ment. Dis., 1958, 127, 1720.Google Scholar
13. Kurland, A., J. Nerv. Ment. Dis., 1955, 121, 321329.Google Scholar
14. Lehmann, H., Canad. Med. ass. J., 1955, 72, 9199.Google Scholar
15. MacDonald, R., and Shields Watts, T. P., Brit. Med. J., 1959, i, 549.Google Scholar
16. Madgwick, J. R. A., McNeill, D. L. M., Driver, M., and Preston, G. C., J. Ment. Sci., 1958, 104, 11951197.Google Scholar
17. Malamud, W., and Sands, S. L., Am. J. Psychiat., 1947, 104, 231237.CrossRefGoogle Scholar
18. Milne, H. R., and Berliner, F., J. Ment. Sci., 1958, 104, 873879.CrossRefGoogle Scholar
19. Pennington, V., Med. Times, 1959, 87(11), 1432–37.Google Scholar
20. Perlin, S., and Russell Lee, A., Am. J. Psychiat., 1959, 116, 231243.Google Scholar
21. Rudy, L. H., Rinaldi, F., Costi, E., Himwich, H. E., Tuteur, W., and Glatzer, J., Am. J. Psychiat., 1958, 115, 364.Google Scholar
22. Sherman, L. J., Am. J. Psychiat., 1959, 116, 208214.Google Scholar
23. Tolan, E. J., Peppel, H. H., Am. J. Psychiat., 1959, 115, 935.Google Scholar
24. Wilcox, F., Dis. Nerv. Syst., 1955, 19(3).Google Scholar
25. Winkelman, N. W., Dis. Nerv. Syst., 1959, 20(1), 2730.Google Scholar
26. U.S. Public Health Reports, 1957, 72, 7.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.